Since a decrease, and not an increase, in calretinin expression is associated with the poorest overall survival, this may suggest that, if it is indeed HuR that stabilizes calretinin mRNA, it competes to bind other tumor progression-associated targets. This evidence concerns the gene ELAVL1 and neoplasm.